Predictive Value of CDX2 and SOX2 in Chronic Gastritis and Intestinal-type Gastric Cancer
DOI:
https://doi.org/10.3889/oamjms.2020.5570Keywords:
CDX2, SOX2, Chronic Gastritis, Gastric Cancer, Helicobacter pylori, Intestinal Metaplasia, DysplasiaAbstract
BACKGROUND: Worldwide gastric cancer (GC) ranks sixth in incidence and second in mortality among all malignancies. CDX2 has an essential role in the development and maintenance of intestinal differentiation in the gut and ectopic sites such as intestinal metaplasia (IM) of the stomach. SOX2 contributes to the cell lineages normally found in the stomach, suggesting contribution in gastric differentiation.
AIM: The aim of the study was to assess the expression of CDX2 and SOX2 in chronic gastritis (CG) lesions associated with Helicobacter pylori, IM, or dysplasia as well as in intestinal-type GC.
METHODS: Immunohistochemical staining for CDX2 and SOX2 were applied on archival paraffin blocks from 80 CG cases, 40 intestinal-type GC cases, and 10 controls. CG cases were either of non-specific inflammation or associated with H. pylori infection. GC cases were of intestinal-type only, excluding any other type of GC. Control cases were of minimal gastritis, negative for H. pylori, IM, and dysplasia.
RESULTS: CDX2 expression was correlated with CG associated with H. pylori, IM, and dysplasia as well as with more differentiated and less invasive pattern of intestinal-type GC, while SOX2 expression was correlated with CG negative for H. pylori and IM as well as with less differentiated and more invasive intestinal-type GC.
CONCLUSION: Both CDX2 and SOX2 could predict the behavior of CG disease over time and plan the suitable line of treatment and both proteins could be potential targets for novel therapeutic interventions.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. https://doi.org/10.1002/ijc.31937 PMid:30350310 DOI: https://doi.org/10.1002/ijc.31937
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. GLOBOCAN v1.0. Lyon, France: IARC; 2012. https://doi.org/10.1002/ijc.29210 DOI: https://doi.org/10.1002/ijc.29210
Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res. 1990;50(15):4737-40. PMid:2369748
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15. https://doi.org/10.1016/s1470-2045(12)70137-7 PMid:22575588 DOI: https://doi.org/10.1016/S1470-2045(12)70137-7
Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487-90. https://doi.org/10.1002/ijc.28999 PMid:24889903 DOI: https://doi.org/10.1002/ijc.28999
Nejati S, Karkhah A, Darvish H, Validi M, Ebrahimpour S, Nouri HR. Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. Microb Pathog. 2018;117:43-8. https://doi.org/10.1016/j.micpath.2018.02.016 PMid:29432909 DOI: https://doi.org/10.1016/j.micpath.2018.02.016
Camilo V, Barros R, Sousa S, Magalhães AM, Lopes T, Santos AM, et al. Helicobacter pylori and the BMP pathway regulate CDX2 and SOX2 expression in gastric cells. Carcinogenesis. 2012;33(10):1985-92. https://doi.org/10.1093/carcin/bgs233 PMid:22791809 DOI: https://doi.org/10.1093/carcin/bgs233
Zhang Y, Wang H, Bi C, Xiao Y, Liu Z. Expression of CDX2 in gastric cardia adenocarcinoma and its correlation with H. pylori and cell proliferation. Oncotarget. 2016;7(34):54973-82. https://doi.org/10.18632/oncotarget.10362 PMid:27384681 DOI: https://doi.org/10.18632/oncotarget.10362
Barros R, Camilo V, Pereira B, Freund JN, David L, Almeida R. Pathophysiology of intestinal metaplasia of the stomach: Emphasis on CDX2 regulation. Biochem Soc Trans. 2010;38(2):358-63. https://doi.org/10.1042/bst038035 PMid:20298183 DOI: https://doi.org/10.1042/BST0380358
Hryniuk A, Grainger S, Savory JG, Lohnes D. CDX1 and CDX2 function as tumor suppressors. J Biol Chem. 2014;289(48):33343-54. https://doi.org/10.1074/jbc.m114.583823 PMid:25320087 DOI: https://doi.org/10.1074/jbc.M114.583823
Halder A, Kundu M, Das RN, Chatterjee U, Datta C, Choudhuri MK, et al. CDX2 expression in gastric carcinoma: A clinicopathological study. Indian J Med Paediatr Oncol. 2018;39:52-7. https://doi.org/10.4103/ijmpo.ijmpo_49_17 12. Avilion A, Nicolis S, Pevny L, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003;17(1):126-66. https://doi.org/10.1101/gad.224503 PMid:12514105 DOI: https://doi.org/10.1101/gad.224503
Sarkar A, Hochedlinger K. The sox family of transcription factors: Versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013;12(1):15-30. https://doi.org/10.1016/j.stem.2012.12.007 PMid:23290134 DOI: https://doi.org/10.1016/j.stem.2012.12.007
Arnold K, Sarkar A, Yram MA, Polo JM, Bronson R, Sengupta S, et al. Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell. 2011;9(4):317-29. https://doi.org/10.1016/j.stem.2011.09.001 PMid:21982232 DOI: https://doi.org/10.1016/j.stem.2011.09.001
Tian T, Zhang Y, Wang S, Zhou J, Xu S. Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res. 2012;26(5):336-45. https://doi.org/10.7555/jbr.26.20120045 PMid:23554769 DOI: https://doi.org/10.7555/JBR.26.20120045
Cameiro F, Fukayama M, Grabsoh H, Yasui W. WHO classification of tumors of the stomach in digestive system tumors. In: WHO Classification of Tumors. 5th ed. Geneva, Switzerland: WHO Classification of Tumors Editorial Board; 2019. p. 60-110. https://doi.org/10.1007/978-3-7091-6821-9_2 DOI: https://doi.org/10.1007/978-3-7091-6821-9_2
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/ neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51(8):1371-9. https://doi.org/10.1007/s10620-005-9057-1 PMid:16868827 DOI: https://doi.org/10.1007/s10620-005-9057-1
Correa P. Human gastric carcinogenesis: A multistep and multifactorial process--first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735-40. PMid:1458460
Bao Q, Dai N, Liu Y, Sun Y, Huang X, Li J. Expression of Cdx2 is associated with clinicopathologic features and prognosis of gastric carcinoma. Chin J Cancer Res. 2006;18:105-10. https://doi.org/10.1007/s11670-006-0105-y DOI: https://doi.org/10.1007/s11670-006-0105-y
Fan Z, Li J, Dong B, Huang X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: Correlation with histologic type and implications for prognosis. Clin Cancer Res. 2005;11(17):6162-70. https://doi.org/10.1158/1078-0432.ccr-05-0278 DOI: https://doi.org/10.1158/1078-0432.CCR-05-0278
Harras HF, Mowafy SE. CDX2 and cyclooxygenase-2 immunohistochemical expression in gastric carcinoma: Relationship with clinicopathological features. Egypt J Pathol. 2019;39:123-30.
Camilo V, Barros R, Celestino R, Castro P, Vieira J, Teixeira MR, et al. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer. 2014;14:753. https://doi.org/10.1186/1471-2407-14-753 PMid:25300947 DOI: https://doi.org/10.1186/1471-2407-14-753
Yang L, Xu JF, Kang Q, Li AQ, Jin P, Wang X, et al. Predictive value of stemness factor Sox2 in gastric cancer is associated with tumor location and stage. PLoS One. 2017;12(1):e0169124. https://doi.org/10.1371/journal.pone.0169124 PMid:28046028 DOI: https://doi.org/10.1371/journal.pone.0169124
Saha AK, Maitra S, Hazra SC. Epidemiology of gastric cancer in the gangetic areas of West Bengal. ISRN Gastroenterol. 2013;2013:823483. https://doi.org/10.1155/2013/823483 PMid:24251042 DOI: https://doi.org/10.1155/2013/823483
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health 2016;4(9):e609-16. https://doi.org/10.1016/s2214-109x(16)30143-7 PMid:27470177 DOI: https://doi.org/10.1016/S2214-109X(16)30143-7
Saito M, Okayama H, Saito K, Ando J, Kumamoto K, Nakamura I, et al. CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer. Oncol Lett. 2017;14(5):6184- 90. https://doi.org/10.3892/ol.2017.6956 PMid:29113265 DOI: https://doi.org/10.3892/ol.2017.6956
Asano N, Imatani A, Watanabe T, Fushiya J, Kondo Y, Jin X, et al. Cdx2 expression and intestinal metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses. Cancer Res. 2016;76(5):1135-45. https://doi.org/10.1158/0008-5472.can-15-2272 PMid:26759244 DOI: https://doi.org/10.1158/0008-5472.CAN-15-2272
Bornschein J, Wex T, Peitz U, Kuester D, Roessner A, Malfertheiner P. The combined presence of H. pylori infection and gastro-oesophageal reflux disease leads to an up-regulation of CDX2 gene expression in antrum and cardia. J Clin Pathol 2009;62(3):254-9. https://doi.org/10.1136/jcp.2008.060061 PMid:19251954 DOI: https://doi.org/10.1136/jcp.2008.060061
Xiao FM, Sun Y, Tian H. CDX2 expression in gastric samples and correlation with H. pylori infection. Gastric Liver Dis. 2009;18:550-2.
Vauhkonen M, Vauhkonen H, Sipponen P. Helicobacter pylori infection induces a reversible expression of the CDX2 transcription factor protein in human gastric epithelium. Scand J Gastroenterol. 2008;43(8):915-21. https://doi.org/10.1080/00365520802014841 PMid:19086163 DOI: https://doi.org/10.1080/00365520802014841
Shiotani A, Uedo N, Iishi H, Tatsuta M, Ishiguro S, Nakae Y, et al. Re-expression of sonic hedgehog and reduction of CDX2 after Helicobacter pylori eradication prior to incomplete intestinal metaplasia. Int J Cancer. 2007;121(6):1182-9. https://doi.org/10.1002/ijc.22835 PMid:17520681 DOI: https://doi.org/10.1002/ijc.22835
Kang JM, Lee BH, Kim N, Lee HS, Lee HE, Park JH, et al. CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. J Korean Med Sci. 2011;26(5):647-53. https://doi.org/10.3346/jkms.2011.26.5.647 PMid:21532856 DOI: https://doi.org/10.3346/jkms.2011.26.5.647
Camilo V, Garrido M, Valente P, Ricardo S, Amaral AL, Barros R, et al. Differentiation reprogramming in gastric intestinal metaplasia and dysplasia: Role of SOX2 and CDX2. Histopathology. 2015;66(3):343-50. https://doi.org/10.1111/his.12544 PMid:25196071 DOI: https://doi.org/10.1111/his.12544
Kim HS, Lee JS, Freund JN, Min KW, Lee JS, Kim W, et al. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions. J Gastroenterol Hepatol. 2006;21(2):438- 42. https://doi.org/10.1111/j.1440-1746.2005.03933.x PMid:16509871 DOI: https://doi.org/10.1111/j.1440-1746.2005.03933.x
Rugge M, Ingravallo G, Farinati F, Russo VM, Zaninotto G, Alvisi V. Re: CDX2 homeotic gene expression in gastric noninvasive neoplasia. Am J Surg Pathol. 2004;28(6):834-5. PMid:15166679 DOI: https://doi.org/10.1097/01.pas.0000126776.65815.48
Mizoshita T, Tsukamoto T, Nakanishi H, Inada K, Ogasawara N, Joh T, et al. Expression of Cdx2 and the phenotype of advanced gastric cancers: Relationship with prognosis. J Cancer Res Clin Oncol. 2003;129(12):727-34. https://doi.org/10.1007/s00432-003-0499-6 PMid:14557879 DOI: https://doi.org/10.1007/s00432-003-0499-6
Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32-41. PMid:7776992 DOI: https://doi.org/10.1056/NEJM199507063330107
Wang XT, Wei WY, Kong FB, Lian C, Luo W, Xiao Q, et al. Prognostic significance of CDX2 immunohistochemical expression in gastric cancer: A meta-analysis of published literatures. J Exp Clin Cancer Res. 2012;31(1):98. https://doi.org/10.1186/1756-9966-31-98 PMid:23181722 DOI: https://doi.org/10.1186/1756-9966-31-98
Qin R, Wang NN, Chu J, Wang X. Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions. World J Gastroenterol. 2012;18(25):3296-302. PMid:22783055
Mizoshita T, Tsukamoto T, Inada K, Ogasawara N, Hirata A, Kato S, et al. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa. Pathol Int. 2004;54(6):392- 400. https://doi.org/10.1111/j.1440-1827.2004.01647.x PMid:15144397 DOI: https://doi.org/10.1111/j.1440-1827.2004.01647.x
Roessler K, Mönig SP, Schneider PM, Hanisch FG, Landsberg S, Thiele J, et al. Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis. World J Gastroenterol. 2005;11(21):3182-8. https://doi.org/10.3748/wjg.v11.i21.3182 PMid:15929165 DOI: https://doi.org/10.3748/wjg.v11.i21.3182
Sarkar A, Huebner AJ, Sulahian R, Anselmo A, Xu X, Flattery K. Sox2 suppresses gastric tumorigenesis in mice. Cell Rep. 2016;16:1929-41. https://doi.org/10.1016/j.celrep.2016.07.034 PMid:27498859 DOI: https://doi.org/10.1016/j.celrep.2016.07.034
Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res. 2012;40(14):6725- 40. https://doi.org/10.1093/nar/gks360 PMid:22561374 DOI: https://doi.org/10.1093/nar/gks360
Basati G, Mohammadpour H, Razavi AE. Association of high expression levels of SOX2, NANOG, and OCT4 in gastric cancer tumor tissues with progression and poor prognosis. J Gastroint Can. 2020;51:41-7. https://doi.org/10.1007/s12029-018-00200-x PMid:30628031 DOI: https://doi.org/10.1007/s12029-018-00200-x
Hütz K, Mejías-Luque R, Farsakova K, Ogris M, Krebs S, Anton M, et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis. 2014;35(4):942-50. https://doi.org/10.1093/carcin/bgt410 PMid:24325912 DOI: https://doi.org/10.1093/carcin/bgt410
Wang S, Tie J, Wang R, Hu F, Gao L, Wang W, et al. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN. Cancer Lett. 2015;358(2):210- 9. https://doi.org/10.1016/j.canlet.2014.12.045 PMid:25543086 DOI: https://doi.org/10.1016/j.canlet.2014.12.045
Khalili M, Vasei M, Khalili D, Alimoghaddam K, Sadeghizadeh M, Mowla SJ. Downregulation of the genes involved in reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in gastric adenocarcinoma. J Gastrointest Cancer. 2015;46(3):251- 8. https://doi.org/10.1007/s12029-015-9695-2 PMid:25904219 DOI: https://doi.org/10.1007/s12029-015-9695-2
Carrasco-Garcia E, Santos JC, Garcia I, Brianti M, García- Puga M, Pedrazzoli J, et al. Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res. 2016;6(4):701-13. PMid:27186426
Yoon JH, Choi SS, Kim O, Choi WS, Park YK, Nam SW, et al. Inactivation of NKX6.3 in the stomach leads to abnormal expression of CDX2 and SOX2 required for gastric-to-intestinal transdifferentiation. Mod Pathol. 2016;29(2):194-208. https://doi.org/10.1038/modpathol.2015.150 PMid:26743476 DOI: https://doi.org/10.1038/modpathol.2015.150
Tsukamoto T, Inada K, Tanaka H, Mizoshita T, Mihara M, Ushijima T, et al. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: Inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol. 2004;130(3):135-45. https://doi.org/10.1007/s00432-003-0519-6 PMid:14655050 DOI: https://doi.org/10.1007/s00432-003-0519-6
Asonuma S, Imatani A, Asano N, Oikawa T, Konishi H, Iijima K, et al. Helicobacter pylori induces gastric mucosal intestinal metaplasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression. Am J Physiol Gastrointest Liver Physiol. 2009;297(2):G312-22. https://doi.org/10.1152/ ajpgi.00518.2007 PMid:19520737 DOI: https://doi.org/10.1152/ajpgi.00518.2007
Barros R, da Costa LT, Pinto-de-Sousa J, Duluc I, Freund JN, David L, et al. CDX2 autoregulation in human intestinal metaplasia of the stomach: Impact on the stability of the phenotype. Gut. 2011;60(3):290-8. https://doi.org/10.1136/gut.2010.222323 PMid:21148572 DOI: https://doi.org/10.1136/gut.2010.222323
Du XM, Wang LH, Chen XW, Li YX, Li YC, Cao YW. Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis. J Huazhong Univ Sci Technol Med Sci. 2016;36(3):305- 12. https://doi.org/10.1007/s11596-016-1584-9 PMid:27376796 DOI: https://doi.org/10.1007/s11596-016-1584-9
Lin S, Qi W, Han K, Gan Z, Yao Y, Miu D. Prognostic value of SOX2 in digestive tumors: A meta-analysis. Hepatogastroenterology. 2014;61(133):1274-8. PMid:25436295
Cobler L, Pera M, Garrido M, Iglesias M, de Bolós C. CDX2 can be regulated through the signalling pathways activated by IL-6 in gastric cells. Biochim Biophys Acta. 2014;1839:785-92. https://doi.org/10.1016/j.bbagrm.2014.06.009 PMid:24953186 DOI: https://doi.org/10.1016/j.bbagrm.2014.06.009
Kuzmichev AN, Kim SK, D’Alessio AC, Chenoweth JG, Wittko IM, Campanati L, et al. Sox2 acts through Sox21 to regulate transcription in pluripotent and differentiated cells. Curr Biol. 2012;22(18):1705-10. https://doi.org/10.1016/j.cub.2012.07.013 PMid:22902753 DOI: https://doi.org/10.1016/j.cub.2012.07.013
Raghoebir L, Bakker ER, Mills JC, Swagemakers S, Kempen MB, Munck AB, et al. SOX2 redirects the developmental fate of the intestinal epithelium toward a premature gastric phenotype. J Mol Cell Biol. 2012;4(6):377-85. https://doi.org/10.1093/jmcb/mjs030 PMid:22679103 DOI: https://doi.org/10.1093/jmcb/mjs030
Downloads
Published
How to Cite
License
Copyright (c) 2020 Noha Helal, Zeinab Omran, Tarek Aboushousha, Magdy Youssef , Afkar Badawy, Mohammed Aboul-Ezz, Mona M. Moussa (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
